touchLIVE MEETING

Applying the latest data to move beyond seizure control for people with severe epilepsy

Watch Time: 45 mins (Part 1); 9 mins (Part 2)

Faculty Presenters: Professor Ley Sander; Dr Kerstin Alexandra Klotz; Prof. Pasquale Striano

to access this content

This activity has been sponsored by GW Pharmaceuticals, plc. GW Pharmaceuticals, plc., provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope.

This content is for Healthcare Professionals only.

Please confirm that you are a healthcare professional.

Decline

This activity has been sponsored by GW Pharmaceuticals, plc. GW Pharmaceuticals, plc., provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope.

Epilepsy, Paediatric Neurology Watch Time: 45 mins (Part 1); 9 mins (Part 2)

touchLIVE MEETING Applying the latest data to move beyond seizure control for people with severe epilepsy

Keep up to date on the latest developments by watching this webinar discussing key issues in the unmet needs beyond seizure control in people with severe epilepsy, and how to improve patient management, focussing on:

  1. Recognizing unmet medical needs in severe epilepsy beyond control of clinical seizures
  2. Evaluating the latest translational research and clinical findings for patients with frequent seizures, and their carers and family
  3. Reviewing how lessons on patient and caregiver support can be incorporated into daily practice

Part 1: Watch the webinar with three internationally renowned experts discussing unmet needs beyond seizure for people with severe epilepsy and how to improve patient management Watch Now
Part 2: Watch the interview providing the highlights of the webinar Watch Now

  • Part 1: Webinar
Next Chapter
Introduction
Watch Time: 00:00
What are the key unmet medical needs remaining for people with severe epilepsy?
Watch Time: 02:29
PANEL DISCUSSION
Watch Time: 09:26
Improving quality of life for people with severe epilepsy: focus on comorbidities
Watch Time: 15:01
PANEL DISCUSSION
Watch Time: 22:44
Audience questions and close
Watch Time: 29:14
Video Player Controls:
 
Leave Feedback
Downloads

View and download resources from this activity to support your learning or share with colleagues.

  • Part 2: Expert Interviews
Leave Feedback
Professor Ley Sander
Watch Time: 09:00
Professor of Neurology and Clinical Epilepsy, National Hospital for Neurology & Neurosurgery, Queen Square, London, UK

Professor Ley Sander discusses the challenges and unmet needs that people with epilepsy still face today. Also focusing on what more can be done to improve the lives of people with severe epilepsy.

 
Leave Feedback
Interview Questions

In this interview, Professor Ley Sander answers the following questions:

  • Beyond seizure control, what are the key unmet medical needs for people with severe epilepsy particularly in terms of quality of life and daily living?
  • In your opinion, how can quality of life in people with epilepsy, and their caregivers and family be improved?
  • Can treating comorbidities improve quality of life for people with severe epilepsy, and their caregivers and family?
  • In terms of the potential impact of drug therapies on comorbidities, in your opinion how best can any changes in QoL be assessed?
  • Overall, what more can be done to improve the lives of people with severe epilepsy?
Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Despite the availability of a wide variety of anti-epileptic drugs, there is still a clear unmet medical need; it is estimated that in 30–40% of all people with epilepsy, the disease is refractory to treatment, and patients continue to experience seizures.1

Consequently, people with uncontrolled severe epilepsy experience significant impact on quality of life and activities of daily living.2

For this touchLIVE MEETING webinar, three leading experts will be discussing key issues in the treatment and management of severe epilepsy, focussing on:

  1. Recognizing unmet medical needs in severe epilepsy beyond control of clinical seizures
  2. Evaluating the latest translational research and clinical findings for patients with frequent seizures, and their carers and family
  3. Reviewing how lessons on patient and caregiver support can be incorporated into daily practice
Learning Objectives

After watching this activity, you should be able to:

  • Recognise the unmet medical needs in severe epilepsy beyond control of clinical seizures
  • Evaluate the latest translatable and clinical findings for patients with frequent seizures, and their carers and family
  • Review how lessons on patient and caregiver support from the COVID-19 pandemic can be incorporated into daily practice
Faculty & Disclosures
Professor Ley Sander

Professor of Neurology and Clinical Epilepsy, National Hospital for Neurology & Neurosurgery, Queen Square, London, UK

Ley Sander is Professor of Neurology and Clinical Epilepsy and Honorary Consultant Neurologist with a specialist interest in epilepsy. read more

In this role, he has approximately 1,200 people with epilepsy under his neurological care. He heads the Department of Clinical and Experimental Epilepsy at the National Hospital for Neurology & Neurosurgery and is the Medical Director of the Chalfont Centre for Epilepsy in Buckinghamshire. Ley Sander is also the Scientific Director of Stichting Epilepsie Instellingen Nederland in Heemstede, the Netherlands. He qualified in medicine at the University of Parana in Curitiba, Brazil and then completed his specialist training in neurology at St Thomas Hospital and at the National Hospital for Neurology and Neurosurgery in London. He obtained his PhD in clinical neurosciences at the University of London and is an elected fellow of the Royal College of Physicians.

Professor Sander has received research grants from Medtronic and UCB, received honoraria as a speaker in virtual and presential events sponsored by Arvelle Therapeutics, Eisai, GW Pharmaceuticals Plc, Novartis, UCB and Zogenix, and for participation on advisory boards for Arvelle, UCB and Zogenix. Professor Sander has, or his department has, undertaken, or are undertaking, studies funded by research grants from Medtronic and UCB. He has not, nor has any members of his family, owned shares or equities in pharmaceutical or medical device companies.

Dr Kerstin Alexandra Klotz

Paediatric Neurologist, University of Freiburg, Freiburg, Germany

Dr. Alexandra Klotz is head of the pediatric epileptology section of the Department of Neuropediatrics and Muscle Disorders at the University Hospital Freiburg, Germany. read more

She is also a fellow of the Berta Ottenstein program, a three year research fellowship. Dr. Klotz clinical as well as scientific work is the management of rare and difficult to treat epilepsies in children. Her main research interests are Cannabinoids in the treatment of epilepsy and comorbidities in patients with hypothalamic hamartoma and other epilepsies. Dr. Klotz is member of the European Reference Network EpiCARE and of the Freiburg Center of rare diseases. She is also a principal investigator on different clinical trials to advance the development of new treatment options for children with drug-resistant epilepsies.

Dr Klotz has received speaker fees and served on advisory boards for EISAI, GW Pharmaceuticals Plc., Zogenix, PTC Therapeutics GmbH Germany and Neuraxpharm.

Prof. Pasquale Striano

Associate Professor, Università degli Studi di Genova, Genova, Italy

Prof. Striano is actively involved in research projects in Italy, Europe and worldwide. He is a board member of Italian League Against Epilepsy (LICE), a scientific association that is focused on promoting knowledge of epilepsy among people and among physicians to improve the care of patients. The collaborative network of LICE is actively working on both International and European projects. read more

Prof. Striano is an associate partner of the EUROEPINOMICS consortium for the study of genetic epilepsies through next-generation sequencing techniques. The project involves the sequencing of coding regions of the genome of patients with undiagnosed epileptic encephalopathies and familiar forms with dominant or recessive inheritance. Prof. Striano has received The International League Against Epilepsy Young Investigator Award at the European Congress of Epileptology, London, November 2012. From 2013, he has been a member of the Pediatric Committee of Italian Medicines Agency.

Prof. Striano has received speaker fees and has participated in advisory boards for Biomarin, GW Pharmaceuticals and Zogenix, and has received research funding from Eisai ENECTA BV, GW Pharmaceuticals Plc and Kolfarma Srl.

References
References
  1. Laxer KD, Trinka E, Hirsch LJ, et al. Epilepsy Behav, 2014;37:59-70.
  2. Berto P, Pharmacoeconomics, 2002;20:1039-59.
  3. Sperling MR, O'Connor MJ. Ann Neurol 1990;28(3):320-8.
Feedback Close
Feedback

Please provide feedback for this touchLIVE MEETING on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72